Rapport Therapeutics, Inc.

RAPP · Nasdaq · United States

Share price · RAPP

$23.40-25.61 (-52.25%) 3M

close as of 2026-11-18 · 24h delayed · vol 731K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RAPP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026-18.3%

    Nothing announced by RAPP that day or the session before.

  2. 21 Oct 2026-14.7%
  3. 23 Sep 2026-17.7%

    Nothing announced by RAPP that day or the session before.

  4. 6 Aug 2026+9.2%
  5. 12 Jun 2026+9.1%

    Nothing announced by RAPP that day or the session before.

  6. 7 May 2026+7.7%
  7. 20 Apr 2026-6.5%

    Nothing announced by RAPP that day or the session before.

  8. 16 Apr 2026+7.7%

    Nothing announced by RAPP that day or the session before.

  9. 2 Apr 2026+6.0%

    Nothing announced by RAPP that day or the session before.

  10. 31 Mar 2026+13.0%

Share of unusual movement by asset

For each asset, the share of RAPP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
AMPA receptor (TARP γ8-dependent)Small molecule
Epilepsy
Focal Onset Seizures

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
RAP-219Phase 2Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Est. primary completion 2028-02-03 · NCT07219407 · CT.gov ↗
What to watch
2029 (2)
July 2029 (2)
RAP-219Phase 3Focal Seizure, Epilepsy, Focal Epilepsy
Est. primary completion 2029-07 · NCT07563881 · CT.gov ↗
What to watch
RAP-219Phase 3Focal Seizure, Epilepsy, Focal Epilepsy
Est. primary completion 2029-07 · NCT07594119 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 October 2026Topline resultRAP-219Phase 2 of RAP-219 in bipolar mania met its primary endpoint
Rapport Therapeutics, Inc. · Source ↗
8 September 2025Topline resultRAP-219Phase 2a RAP-219-FOS-201 of RAP-219 in focal onset seizures: positive topline results
Rapport Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$34M$75M+ $320M short-term inv.$40M-$42M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$51M$64M+ $372M short-term inv.$57M-$41M operating cash flowreport ↗
2026-Q1$20M$33M$78M+ $399M short-term inv.$20M-$13M operating cash flowreport ↗
2025-Q3—$22M$251M+ $262M short-term inv.$27M-$17M operating cash flowreport ↗
2025-Q2$0$23M$55M+ $205M short-term inv.$27M-$25M operating cash flowreport ↗
2025-Q1$0$20M$58M+ $228M short-term inv.$24M-$20M operating cash flowreport ↗
2024-Q3—$16M$39M+ $281M short-term inv.$18M-$16M operating cash flowreport ↗
2024-Q2—$16M$110M+ $226M short-term inv.$18M-$16M operating cash flowreport ↗
2024-Q1—$13M$74M$23M-$18M operating cash flowreport ↗
2023-Q3—$7.6M$159M$8.7M-$5.4M operating cash flowreport ↗
2023-Q2—$4.7M$80M$6.4Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$95M$53M+ $438M short-term inv.$28M-$87M operating cash flowreport ↗

Rapport Therapeutics reported full-year 2025 results with revenue not disclosed. R&D spend was $94.8M, up 55.5% YoY, and the company posted a net loss of $111.5M for 2025 versus $78.3M in 2024, including a Q4 net loss of $33.8M. The company ended the period with $490.5M in cash, cash equivalents, and short-term investments, excluding restricted cash, which it expects to fund operations into the second half of 2029.

RAP-219's Phase 2a trial in focal onset seizures met its primary endpoints, with a 77.8% median reduction in clinical seizure frequency; the Phase 3 program in FOS is expected to begin in Q2 2026, with a Phase 3 trial in primary generalized tonic-clonic seizures planned for the first half of 2027. Topline results from the Phase 2 bipolar mania trial are expected in the first half of 2027, the FDA lifted the clinical hold on the diabetic peripheral neuropathic pain program with further investment deferred, and the company entered a collaboration with Tenacia Biotechnology for RAP-219 in Greater China, with a $20M upfront payment and up to approximately $308M in potential milestones plus tiered royalties. IND-enabling activities are also underway for a long-acting injectable formulation and the α6β4 program.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$61M$57M+ $248M short-term inv.$20M-$65M operating cash flowreport ↗
2023-FY—$28M$70M+ $77M short-term inv.$8.7M-$27M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 11 purchases ($22.0M), 66 sales ($46.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerAward / grant238,095$21.00$5.0MForm 4
2026-10-30Third Rock Ventures V, L.P.; Third Rock Ventures GP V, LP; TRV GP V, LLC; Third Rock Ventures VI, L.P.; Third Rock Ventures GP VI, L.P.; TRV GP VI, LLC · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerAward / grant1,190,476$21.00$25.0MForm 4
2026-10-28HEALY JAMES · directorOpen-market purchase952,380$21.00$20.0MForm 4
2026-10-28HEALY JAMES · directorOpen-market purchase6,395$21.00$134KForm 4
2026-10-28HEALY JAMES · directorOpen-market purchase3,772$21.00$79KForm 4
2026-10-28HEALY JAMES · directorOpen-market purchase6,933$21.00$146KForm 4
2026-10-23Sanchez Ramiro · directorOpen-market purchase3,600$27.35$98KForm 4
2026-10-22MARAGANORE JOHN · directorOpen-market purchase8,239$26.38$217KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 147 reporting institutions held 52.5M shares ($1.6B, 88.5% of shares outstanding).

#InstitutionSharesValue
1FMR LLC7,168,939$224.3M
2TRV GP V, LLC7,135,233$223.3M
3ARCH Venture Management, LLC3,728,738$116.7M
4Capital International Investors3,097,973$96.9M
5Cormorant Asset Management, LP2,957,521$92.5M
6GOLDMAN SACHS GROUP INC2,942,251$92.1M
7BlackRock, Inc.2,505,955$78.4M
8Sofinnova Investments, Inc.1,904,408$59.6M
9JOHNSON & JOHNSON1,784,517$55.8M
10Polar Capital Holdings Plc1,642,461$51.4M
11BAKER BROS. ADVISORS LP1,547,090$48.4M
12Vestal Point Capital, LP1,436,229$44.9M
13VANGUARD CAPITAL MANAGEMENT LLC1,325,082$41.5M
14TRV GP VI, LLC969,218$30.3M
15UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC918,866$28.8M